Overview of Alzheimer's Disease
Alzheimer's disease is a progressive neurodegenerative disorder that destroys neurons through abnormal protein buildup, leading to memory loss, cognitive decline, and eventually complete dependence on caregivers. For nurses, understanding the underlying mechanisms matters because the medications you'll study in this unit target specific parts of this disease process.
Diagnosis relies on a combination of cognitive testing, brain imaging, and biomarker analysis. While age and genetics are major risk factors, lifestyle factors also influence risk. Symptoms progress through distinct stages, from mild forgetfulness to severe cognitive and physical impairment.
Mechanisms of Alzheimer's Disease
Two types of abnormal protein accumulation drive the disease:
- Beta-amyloid plaques form sticky clusters between neurons. These plaques interfere with cell-to-cell communication and trigger an inflammatory response in surrounding tissue.
- Neurofibrillary tangles are twisted fibers of tau protein that accumulate inside neurons. Tau normally stabilizes microtubules (the cell's internal transport system), but when it becomes abnormally twisted, microtubules collapse. Nutrients and signaling molecules can no longer move through the neuron properly, and the cell eventually dies.
Together, plaques and tangles cause synaptic dysfunction, meaning neurons can't release and receive neurotransmitters effectively. As more neurons die, entire brain regions shrink (atrophy), producing the cognitive symptoms you'll see clinically.
The two regions hit earliest and hardest:
- Hippocampus: Critical for learning and forming new memories. Damage here explains why short-term memory loss is typically the first symptom.
- Cerebral cortex: Responsible for reasoning, language, and decision-making. As the disease spreads to cortical areas, patients lose the ability to perform complex tasks and eventually lose language skills.
Neurobiological Factors in Alzheimer's Disease
Several interconnected biological processes contribute to disease progression:
- Cholinergic system impairment: Neurons that use acetylcholine (ACh) as their neurotransmitter are among the first to degenerate. This is directly relevant to pharmacology because the main drug class for Alzheimer's (cholinesterase inhibitors) targets this deficit.
- Neurodegeneration: Progressive, irreversible loss of neuronal structure and function across affected brain regions.
- Neurotransmitter imbalances: Beyond acetylcholine, other systems are disrupted, including glutamate signaling. Excess glutamate causes excitotoxicity, which damages neurons. This is the target of memantine, another drug you'll study.
- Neuroinflammation: Microglia (the brain's immune cells) become chronically activated around amyloid plaques, releasing inflammatory molecules that worsen neuronal damage.
- Oxidative stress: An imbalance between free radicals and antioxidants increases cellular damage, particularly in metabolically active neurons.
- Blood-brain barrier changes: Alterations in this protective barrier may allow harmful substances into the brain and impair clearance of toxic proteins like beta-amyloid.
- Reduced neuroplasticity: The brain's ability to form new neural connections and compensate for damage diminishes as the disease progresses.
Symptoms of Alzheimer's Progression
Early stage is characterized by memory loss and mild cognitive impairment:
- Difficulty remembering recent events or newly learned information. Patients often repeat questions or statements, forget appointments, and misplace items.
- Trouble with complex tasks like planning, organizing, and problem-solving. Examples include struggling to manage finances or getting lost in familiar places.
Middle stage brings worsening memory loss, language difficulties, and behavioral changes:
- Inability to recall personal history or recognize familiar people. Patients become confused about time, place, and events, and may wander.
- Language deterioration: struggling to find words, using incorrect words, reduced vocabulary, and difficulty following conversations or understanding instructions.
- Mood and behavioral changes including apathy, depression, irritability, restlessness, agitation, and pacing. Patients often lose interest in activities they previously enjoyed.
Late stage involves severe cognitive decline, physical deterioration, and total dependence on caregivers:
- Inability to communicate effectively or respond to the environment. Patients may not recognize loved ones and become largely unresponsive to stimuli.
- Physical decline including loss of mobility, balance, and coordination, along with incontinence and difficulty swallowing. Most patients become bedridden.
- Complete dependence for all activities of daily living, with increased susceptibility to complications such as aspiration pneumonia and pressure ulcers.
Causes and Diagnosis of Alzheimer's
Risk factors fall into three categories:
- Age is the single greatest risk factor. Prevalence increases significantly after age 65, roughly doubling every five years after that.
- Genetic factors operate in two ways. Rare familial Alzheimer's is caused by specific inherited gene mutations (in genes like APP, PSEN1, or PSEN2) and typically develops early, in a patient's 30s to 50s. Far more common is the APOE-e4 allele, which increases the likelihood of developing Alzheimer's but does not guarantee it.
- Environmental and lifestyle factors such as history of head trauma, cardiovascular disease, and low educational attainment may increase risk. Conversely, regular exercise, a balanced diet, and cognitive engagement may be protective.
Diagnostic methods involve multiple approaches used together:
- Clinical evaluation: Review of symptoms, family history, and overall health, combined with standardized cognitive tests to assess memory, language, and problem-solving. Common tools include the Mini-Mental State Exam (MMSE) and the Montreal Cognitive Assessment (MoCA).
- Neuroimaging: MRI detects brain atrophy and structural changes, helping rule out other causes of cognitive decline (tumors, strokes). PET scans use radioactive tracers to visualize beta-amyloid and tau accumulation directly, and to assess brain metabolism.
- Biomarker analysis: Cerebrospinal fluid (CSF) testing measures levels of beta-amyloid and tau proteins. A pattern of lower beta-amyloid (because it's depositing in plaques rather than flowing freely) and higher tau levels supports an Alzheimer's diagnosis. Blood-based biomarker tests are emerging and show promise but are still being validated for routine clinical use.